Literature DB >> 16157536

Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG.

Daniela Pellegrino1, Ali A Bonab, Stephen C Dragotakes, Justin T Pitman, Giuliano Mariani, Edward A Carter.   

Abstract

UNLABELLED: (18)F-FDG and (18)F-FDG-labeled white blood cells ((18)F-FDG-WBCs) are valuable radiopharmaceuticals for imaging focal sites of inflammation and infection. In the present study, the imaging properties of both radiotracers were compared in sterile and septic inflammation models.
METHODS: Groups of adult male Sprague-Dawley rats (100-120 g) were injected in the left posterior thigh muscle with saline solution (group 1: controls, n = 15), 0.100 mL of turpentine oil (group 2: sterile inflammation, n = 26), 10(9) viable Escherichia coli bacteria (group 3: E. coli septic inflammation, n = 29), or 10(8) viable Pseudomonas aeruginosa bacteria (group 4: P. aeruginosa septic inflammation, n = 25). Twenty-four hours later, the animals were divided into 2 groups: One received (18)F-FDG intravenously and the other received human white blood cells (WBCs) labeled in vitro with (18)F-FDG injected intravenously. Biodistribution and microPET studies were performed 1 h after radiotracer injection. One hour after injection with cell-associated or free (18)F-FDG, phosphorimaging of abscess and contralateral muscle was performed in specimens collected from animals in groups 1, 2, and 3. The region of interest was selected within the abscess wall and values were converted to kBq/g using a (14)C calibration standard curve. Thin-layer radiochromatography (TLRC) was performed to study the chemical forms of (18)F within the WBCs.
RESULTS: Whole-body biodistribution demonstrated a significantly higher uptake ratio of (18)F-FDG-WBCs compared with (18)F-FDG in all sterile and septic inflammation models (t test: sterile, P = 0.048; E. coli, P = 0.040; P. aeruginosa, P = 0.037). microPET imaging confirmed the greater performance of (18)F-FDG-WBCs versus (18)F-FDG in the sterile inflammation model and in both E. coli and P. aeruginosa septic models. Phosphorimaging analysis showed higher (18)F-FDG-WBC uptake than (18)F-FDG in the sterile inflammation and P. aeruginosa septic models and similar tissue uptake in the E. coli septic model. Time course labeling and TLRC of lysed WBCs demonstrated that (18)F-FDG was retained as (18)F-FDG-6-phosphate inside WBCs for at least 2 h, corresponding to the time frame of analysis.
CONCLUSION: (18)F-FDG-WBCs gave better results compared with (18)F-FDG in all sterile and septic inflammation models. These data suggest that (18)F-FDG-WBC PET may be a useful technique for tracking focal inflammatory lesions in the body.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157536

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  34 in total

1.  The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions.

Authors:  Sabire Yılmaz; Meltem Ocak; Sertac Asa; Anar Aliyev; Meftune Ozhan; Metin Halac; Sait Sager; Levent Kabasakal; Kerim Sonmezoglu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-26       Impact factor: 9.236

2.  Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2017-10       Impact factor: 5.952

Review 3.  Is there still a role for SPECT-CT in oncology in the PET-CT era?

Authors:  Rodney J Hicks; Michael S Hofman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

4.  Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.

Authors:  Jyotsna Bhatt; Archana Mukherjee; Aruna Korde; Mukesh Kumar; Haladhar Dev Sarma; Ashutosh Dash
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

5.  FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection: response to Lazzeri et al.

Authors:  Sabire Yilmaz; Betül Vatankulu; Ozgül Ekmekciogu; Sait Sager; Metin Halac
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-07       Impact factor: 9.236

Review 6.  Radiotracers used for the scintigraphic detection of infection and inflammation.

Authors:  Chris Tsopelas
Journal:  ScientificWorldJournal       Date:  2015-02-08

7.  Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Med       Date:  2017-08       Impact factor: 10.057

8.  PET imaging of bacterial infections with fluorine-18-labeled maltohexaose.

Authors:  Xinghai Ning; Wonewoo Seo; Seungjun Lee; Kiyoko Takemiya; Mohammad Rafi; Xuli Feng; Daiana Weiss; Xiaojian Wang; Larry Williams; Vernon M Camp; Malveaux Eugene; W Robert Taylor; Mark Goodman; Niren Murthy
Journal:  Angew Chem Int Ed Engl       Date:  2014-10-21       Impact factor: 15.336

9.  FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection.

Authors:  Sabire Yılmaz Aksoy; Sertac Asa; Meftune Ozhan; Meltem Ocak; M Sait Sager; Melih Engin Erkan; Metin Halac; Levent Kabasakal; Kerim Sönmezoglu; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

10.  Non-invasive imaging of acute renal allograft rejection in rats using small animal F-FDG-PET.

Authors:  Stefan Reuter; Uta Schnöckel; Rita Schröter; Otmar Schober; Hermann Pavenstädt; Michael Schäfers; Gert Gabriëls; Eberhard Schlatter
Journal:  PLoS One       Date:  2009-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.